2 349

Cited 14 times in

Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide).

Authors
 Suk Ho Byeon  ;  Oh W. Kwon  ;  Ji Hun Song  ;  Sung Eun Kim  ;  Yong Sik Park 
Citation
 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, Vol.247(1) : 35-42, 2009 
Journal Title
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
ISSN
 0721-832X 
Issue Date
2009
MeSH
Administration, Topical ; Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/adverse effects ; Aqueous Humor/physiology ; Bevacizumab ; Diabetic Retinopathy/complications ; Diabetic Retinopathy/drug therapy ; Diabetic Retinopathy/pathology ; Drug Synergism ; Drug Therapy, Combination ; Female ; Humans ; Injections ; Intraocular Pressure/drug effects ; Macular Edema/drug therapy* ; Macular Edema/etiology ; Macular Edema/pathology ; Male ; Middle Aged ; Retinal Vein Occlusion/complications ; Retinal Vein Occlusion/drug therapy* ; Retinal Vein Occlusion/pathology ; Sulfonamides/administration & dosage* ; Sulfonamides/adverse effects ; Thiophenes/administration & dosage* ; Thiophenes/adverse effects ; Timolol/administration & dosage* ; Timolol/adverse effects ; Treatment Outcome ; Visual Acuity/drug effects ; Vitreous Body
Keywords
Bevacizumab ; Pharmacokinetics ; Intravitreal injection ; Macular edema ; Retinal vein obstruction ; Diabetic retinopathy ; OCT ; Retinal thickness
Abstract
BACKGROUND: To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab.

METHODS: Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were enrolled. These patients were randomly assigned into 2 groups: timolol-dorzolamide drops twice daily (n = 19) or no eyedrops (control; n = 19). All patients received 1.25 mg (in 0.05 mL) of bevacizumab intravitreally and were examined before treatment, 1 week after injection, and then every 4 weeks after injection. For each patient, visual acuity (VA), intraocular pressure (IOP), and central retinal thickness (CRT) by optical coherence tomography (OCT) were recorded before injection and at each visit after injection. The mean CRT at each timepoint was considered to directly reflect the biological activities of bevacizumab at those times.

RESULTS: The mean CRT measured by OCT showed a significant decrease 1 week after treatment in both groups, and this difference was maintained for a total of 9 weeks (paired t-test, <0.001). The mean CRT at 1 week post-injection showed no significant between-group difference (p = 0.781). At 5 weeks post-injection, the timolol-dorzolamide group showed a significantly smaller mean CRT than the control group (p = 0.032). The difference in mean CRT between the 2 groups disappeared, however, at 9 weeks post-injection (p = 0.462). In both groups, VA improved significantly 1 week after injection, and these changes were maintained to 9 weeks post-injection in both groups. The mean VA of the 2 groups showed no difference at any time.

CONCLUSIONS: Timolol-dorzolamide aqueous depressant drops may delay the elimination of intravitreal bevacizumab but clinical efficacy of the eyedrops have not been proven in this study.
Full Text
http://link.springer.com/article/10.1007%2Fs00417-008-0917-1
DOI
10.1007/s00417-008-0917-1
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Byeon, Suk Ho(변석호) ORCID logo https://orcid.org/0000-0001-8101-0830
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103636
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links